Acoramidis significantly improves NT-proBNP indices that indicate ATTR-CM disease progression and predict subsequent mortality: insights from the ATTRibute-CM study
Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Spain)
63
presentations
16
followers
7
more
presentations
in this session
Temporal trends and clinical characteristics of variant versus wild-type transthyretin amyloid cardiomyopathy in Asian population: the Korean nationwide cohort study
Impact of the non-invasive diagnostic algorithm on clinical presentation and prognosis in a nationwide multicentric light-chain and transthyretin-related cardiac amyloidosis cohort
Health-related quality of life in patients with symptomatic transthyretin amyloid cardiomyopathy treated with acoramidis: an EQ-5D analysis from the ATTRibute-CM study